Lixte Biotechnology (LIXT)

• Market cap: $4.45M
• 1 day: 3.66%
• 5 days: -3.88%
• 1 month: 32.89%
• 3 months: 5.32%
• 6 months: -20.48%
• Year to date: -13.54%
• 1 year: -5.71%
• 5 years: -94.71%
• 10 years: -94.71%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Employees: 4

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more funds holding

Funds holding: 6 [Q2] → 7 (+1) [Q3]

1.65% more ownership

Funds ownership: 7.93% [Q2] → 9.58% (+1.65%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

4% less capital invested

Capital invested by funds: $424K [Q2] → $409K (-$15K) [Q3]